Skip to NavigationSkip to content

Cancer Drug Fund

Cancer Drug Fund roundly criticised as ‘wastage of resources’

The Cancer Drug Fund (CDF), which has now been absorbed into NICE, previous methods of funding have been fiercely criticised in a new study by UK researchers. The fund, which ran independently between 2010 and 2016, spent £1.27 billion to give patients access to experimental drugs.

AstraZeneca’s wins major drug approval by NICE

AstraZeneca’s Tagrisso (osimertinib) has successfully received endorsement of Britain’s Cancer Drugs Fund that has a reserve of £340 million to fund drugs deemed cost efficient and with evidence of positive results from clinical trials. Tagrisso is the first drug to be approved by the NHS through the newly reformed fund. To achieve this back, AstraZeneca had to demonstrate to the fund, through clinical evidence, that the drug was particularly effective and to provide a discount on the list price for the drug.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches